By tagging its antibody with a molecular key that unlocks the barrier, Roche’s trontinemab quickly permeates the brain. The ...

Q4 2024 Management View CEO Thomas Schinecker emphasized that 2024 was an "excellent year," with overall group sales growing 7%, driven by 9% growth in the base business. Pharma and diagnostics ...

Roche has completed the first part of an early-stage study for trontinemab, a drug designed to clear amyloid which deploys a brain shuttle technology to slip past the protective blood-brain barrier.

Roche reported 3% top-line growth for the full ... Mid-stage data from programs in hemophilia (NXT007) and Alzheimer's (trontinemab) could be sufficient to push these programs to late-stage ...

Investing.com -- UBS made key adjustments to its ratings on major European pharmaceutical companies, downgrading Novartis ...

including EU approval for Vabysmo pre-filled syringe and positive results for trontinemab. New launches included the Accu-Chek CGM and advancements in diagnostics technology. Roche's ...